9
06月
Qidu Pharma Retains Position Among China's Top 100 Pharmaceutical CompaniesFrom September 6-9, the 41st National Pharmaceutical Industry Information Annual Conference and the 2023 China Top 100 Pharmaceutical Companies Ranking Release Ceremony were held in Chengdu. During th
9
06月
Qidu Pharma’s Five Products Were Selected in China's 10th National Drug Procurement ProgramOn December 12, the 10th National Volume-Based Drug Procurement (VBP) tender was held in Shanghai. Shandong Qidu Pharmaceutical Co., Ltd. had five products successfully selected: 1. Ciprofloxacin Lac
9
06月
12 Products Pass or Are Deemed to Pass Consistency Evaluation1. Qidu Pharma’s Osowei® - Omeprazole Sodium Bicarbonate Dry Suspension (I) Approved for Market Launch2.Jisu® - Sodium Bicarbonate Injection (all specifications) pass evaluation, marking Qidu Pharma’s
9
06月
Qidu Biotech’s Self-Developed Serum-Free Medium for Umbilical Cord Mesenchymal Stem Cells Approved for Market LaunchOn May 18, the first serum-free medium independently developed by Qidu Pharma’s Biopharmaceutical Division—Umbilical Cord Mesenchymal Stem Cell Serum-Free Medium (Brand: PeiMeiYou®)—officially entered
9
06月
Qidu Pharma Signs Strategic Cooperation Agreement with Peking University Health Science Center to Establish Joint LaboratoryOn June 20, the signing ceremony for the "Peking University Health Science Center – Qidu Pharma Innovative Formulations Joint Laboratory" was held at the Science and Innovation Center of Peking Univer